Abnormal/JJ
NF-kappa/NN
B/NN
activity/NN
in/IN
T/NN
lymphocytes/NNS
from/IN
patients/NNS
with/IN
systemic/JJ
lupus/NN
erythematosus/NN
is/VBZ
associated/VBN
with/IN
decreased/VBN
p65-RelA/NN
protein/NN
expression/NN
./.

Numerous/JJ
cellular/JJ
and/CC
biochemical/JJ
abnormalities/NNS
in/IN
immune/JJ
regulation/NN
have/VBP
been/VBN
described/VBN
in/IN
patients/NNS
with/IN
systemic/JJ
lupus/NN
erythematosus/NN
(/(
SLE/NN
)/)
,/,
including/VBG
surface/NN
Ag/NN
receptor-initiated/JJ
signaling/NN
events/NNS
and/CC
lymphokine/JJ
production/NN
./.
=====
Because/IN
NF-kappa/NN
B/NN
contributes/VBZ
to/TO
the/DT
transcription/NN
of/IN
numerous/JJ
inflammatory/JJ
genes/NNS
and/CC
has/VBZ
been/VBN
shown/VBN
to/TO
be/VB
a/DT
molecular/JJ
target/NN
of/IN
antiinflammatory/JJ
drugs/NNS
,/,
we/PRP
sought/VBD
to/TO
characterize/VB
the/DT
functional/JJ
role/NN
of/IN
the/DT
NF-kappa/NN
B/NN
protein/NN
complex/NN
in/IN
lupus/JJ|NN
T/NN
cells/NNS
./.
=====
Freshly/RB
isolated/VBN
T/NN
cells/NNS
from/IN
lupus/NN
patients/NNS
,/,
rheumatoid/JJ
arthritis/NN
(/(
RA/NN
)/)
patients/NNS
,/,
and/CC
normal/JJ
individuals/NNS
were/VBD
activated/VBN
physiologically/RB
via/IN
the/DT
TCR/NN
with/IN
anti-CD3/JJ
and/CC
anti-CD28/JJ
Abs/NNS
to/TO
assess/VB
proximal/JJ
membrane/NN
signaling/NN
,/,
and/CC
with/IN
PMA/NN
and/CC
a/DT
calcium/NN
ionophore/NN
(/(
A23187/NN
)/)
to/TO
bypass/VB
membrane-mediated/JJ
signaling/NN
events/NNS
./.
=====
We/PRP
measured/VBD
the/DT
NF-kappa/NN
B/NN
binding/NN
activity/NN
in/IN
nuclear/JJ
extracts/NNS
by/IN
gel/NN
shift/NN
analysis/NN
./.
=====
When/WRB
compared/VBN
with/IN
normal/JJ
cells/NNS
,/,
the/DT
activation/NN
of/IN
NF-kappa/NN
B/NN
activity/NN
in/IN
SLE/NN
patients/NNS
was/VBD
significantly/RB
decreased/VBN
in/IN
SLE/NN
,/,
but/CC
not/RB
in/IN
RA/NN
,/,
patients/NNS
./.
=====
NF-kappa/NN
B/NN
binding/NN
activity/NN
was/VBD
absent/JJ
in/IN
several/JJ
SLE/NN
patients/NNS
who/WP
were/VBD
not/RB
receiving/VBG
any/DT
medication/NN
,/,
including/VBG
corticosteroids/NNS
./.
=====
Also/RB
,/,
NF-kappa/NN
B/NN
activity/NN
remained/VBD
absent/JJ
in/IN
follow-up/JJ
studies/NNS
./.
=====
In/IN
supershift/NN
experiments/NNS
using/VBG
specific/JJ
Abs/NNS
,/,
we/PRP
showed/VBD
that/IN
,/,
in/IN
the/DT
group/NN
of/IN
SLE/NN
patients/NNS
who/WP
displayed/VBD
undetectable/JJ
NF-kappa/NN
B/NN
activity/NN
,/,
p65/NN
complexes/NNS
were/VBD
not/RB
formed/VBN
./.
=====
Finally/RB
,/,
immunoblot/NN
analysis/NN
of/IN
nuclear/JJ
extracts/NNS
showed/VBD
decreased/VBN
or/CC
absent/JJ
p65/NN
protein/NN
levels/NNS
./.
=====
As/IN
p65/NN
complexes/NNS
are/VBP
transcriptionally/RB
active/JJ
in/IN
comparison/NN
to/TO
the/DT
p50/NN
homodimer/NN
,/,
this/DT
novel/JJ
finding/NN
may/MD
provide/VB
insight/NN
on/IN
the/DT
origin/NN
of/IN
abnormal/JJ
cytokine/NN
or/CC
other/JJ
gene/NN
transcription/NN
in/IN
SLE/NN
patients/NNS
./.